Australia's Mayne Pharma agrees to $25 million settlement for not disclosing US price-fixing allegations
South Australia-based pharmaceutical company Mayne Pharma has agreed to pay A$38 million ($25 million) to settle an Australian shareholder class action over the company's failure to disclose alleged anticompetitive conduct in...To view the full article, register now.
Already a subscriber? Click here to view full article